5-(3,5-dimethylpiperidin-1-yl)sulfonyl-N,N-diethyl-3-methyl-1-benzofuran-2-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: 5-(3,5-dimethylpiperidin-1-yl)sulfonyl-N,N-diethyl-3-methyl-1-benzofuran-2-carboxamide
• 化学式: C₂₁H₃₀N₂O₄S
• 分子量: 406.5
• InChiKey: JNZMNQVFIPASOT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  79.2
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans
  申请人：Regen BioPharma, Inc.

  公开号：US20180214413A1

  公开（公告）日：2018-08-02

  The present technology is directed to modulators of nuclear receptor activity, specifically to the modulation of NR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through administration of compounds described herein to humans.

  目前的技术是针对核受体活性调节剂，具体是针对NR2F6活性的调节和利用NR2F6化合物的调节，以及通过将本文描述的化合物用于人体来进行免疫调节和调节癌症干细胞活性。
• HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS
  申请人：Termin Andreas

  公开号：US20090253682A1

  公开（公告）日：2009-10-08

  Heterocyclic derivatives act as Ca channel antagonists. The compositions are useful for treating or relieving Ca channel mediated conditions.

  杂环衍生物作为钙通道拮抗剂。该组合物用于治疗或缓解钙通道介导的疾病。
• Methods of screening compounds that can modulate NR2F6 by displacement of a reference ligand
  申请人：Regen BioPharma, Inc

  公开号：US10088485B2

  公开（公告）日：2018-10-02

  The current invention discloses compositions of matter, protocols and methods of screening test compounds to identifying agonists and antagonists of the orphan nuclear receptor NR2F6 by measuring the ability of a test compound to occupy the active site of NR2F6, in the presence of a reference compound.

  本发明公开了筛选试验化合物的物质组合物、方案和方法，通过测量试验化合物在参比化合物存在的情况下占据 NR2F6 活性位点的能力，确定孤儿核受体 NR2F6 的激动剂和拮抗剂。
• Small molecule agonists and antagonists of NR2F6 activity in animals
  申请人：Zander Therapeutics, Inc.

  公开号：US10472351B2

  公开（公告）日：2019-11-12

  The present technology is directed to modulators of nuclear receptor activity, specifically to the modulation of NR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through administration of compounds described herein to animals.

  本技术针对核受体活性调节剂，特别是针对 NR2F6 活性调节和 NR2F6 利用化合物，以及通过对动物施用本文所述化合物进行免疫调节和癌症干细胞活性调节。
• Small molecule agonists and antagonists of NR2F6 activity
  申请人：ZANDER THERAPEUTICS, INC.

  公开号：US11377442B2

  公开（公告）日：2022-07-05

  The present technology is directed to modulators of nuclear receptor activity, specifically to the modulation of NR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through administration of compounds described herein.

  本技术针对核受体活性调节剂，特别是针对 NR2F6 活性调节和 NR2F6 利用化合物，以及通过服用本文所述化合物进行免疫调节和癌症干细胞活性调节。